Pfenex Inc (NYSEMKT:PFNX)‘s stock had its “outperform” rating restated by stock analysts at William Blair in a report issued on Thursday.

A number of other equities research analysts have also recently commented on the company. Zacks Investment Research upgraded Pfenex from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Wednesday, July 19th. ValuEngine cut Pfenex from a “hold” rating to a “sell” rating in a report on Saturday, June 3rd.

Pfenex (NYSEMKT PFNX) opened at 3.79 on Thursday. The company’s 50-day moving average price is $4.34 and its 200-day moving average price is $5.44. Pfenex has a 12 month low of $3.54 and a 12 month high of $11.35. The stock has a market cap of $88.89 million, a P/E ratio of 24.77 and a beta of 4.65.

Pfenex (NYSEMKT:PFNX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by $0.06. The company had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. Pfenex had a negative net margin of 356.00% and a negative return on equity of 53.20%. Pfenex’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.43) EPS. Equities analysts forecast that Pfenex will post ($2.09) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/11/pfenexs-nysemktpfnx-outperform-rating-reiterated-at-william-blair.html.

In other Pfenex news, Director Jason Grenfell-Gardner acquired 10,000 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were acquired at an average price of $4.51 per share, for a total transaction of $45,100.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $45,100. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in shares of Pfenex by 221.0% in the first quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 22,160 shares during the period. Algert Global LLC raised its position in shares of Pfenex by 207.3% in the first quarter. Algert Global LLC now owns 34,603 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 23,344 shares during the period. LMR Partners LLP purchased a new position in shares of Pfenex during the second quarter valued at $252,000. Nine Chapters Capital Management LLC purchased a new position in shares of Pfenex during the first quarter valued at $265,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Pfenex by 126.7% in the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 31,308 shares during the period.

Pfenex Company Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.